Mirati Therapeutics, Inc. (MRTX)
Chart Events
Performance Outlook
| Previous Close | 86.37 |
| Open | 85.65 |
| Bid | 85.39 x 1400 |
| Ask | 85.55 x 900 |
| Day's Range | 84.92 - 88.08 |
| 52 Week Range | 32.96 - 195.99 |
| Volume | |
| Avg. Volume | 1,621,456 |
| Market Cap | 4.727B |
| Beta (5Y Monthly) | 0.99 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.96 |
| Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 118.46 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for MRTX
Related Research
- Mirati Therapeutics, Inc.Daily – Vickers Top Buyers & Sellers for 01/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat7 months agoArgus Research
- Simply Wall St.
Growth Investors: Industry Analysts Just Upgraded Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenue Forecasts By 16%
Mirati Therapeutics, Inc. ( NASDAQ:MRTX ) shareholders will have a reason to smile today, with the analysts making...
- Simply Wall St.
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- PR Newswire
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 56 new employees with a grant date of August 1, 2022, as equity inducement awards outside of the company's 2022 Equity Incentive Plan (but under the terms of the company's Inducement Plan) and material to the employees' acceptance of employment with the company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
